Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 135OTHER 64NIH 27NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Oligometastatic Squamous Cell Carcinoma of the Head and Neck 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 16Magnetic Resonance Spectroscopy 13Vincristine 8Dexamethasone 6Cyclophosphamide 6Radiotherapy 5Radiation 5Leucovorin 5Lenalidomide 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5dexamethasone acetate 4dexamethasone 21-phosphate 4daratumumab 4auricularum 4X-Rays 4Standard of Care 4Radiotherapy, Conformal 4Practice Guidelines as Topic 4Etoposide 4Cytarabine 4Bortezomib 4Biopsy 4pegaspargase 3Taxes 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Prednisone 3Platinum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × pembrolizumab × 30 days × Clear all
NCT05815927 2026-05-28

PROLoNg

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Recruiting
200 enrolled
Head & Neck

Oligometastatic Squamous Cell Carcinoma of the Head and Neck

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡